- Home
- KZR vs CUE Comparison
KZR vs CUE Comparison
Compare KZR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZR | CUE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 49.6M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KZR | CUE |
|---|---|---|
| Price | $6.20 | $0.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | 34.0K | ★ 1.8M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.53 | $0.23 |
| 52 Week High | $6.65 | $1.54 |
Technical Indicators
Market Signals| Indicator | KZR | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 33.76 |
| Support Level | $6.04 | $0.32 |
| Resistance Level | $6.27 | $0.37 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 33.33 | 18.06 |
Price Performance
Historical ComparisonAbout KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.